 |
 Video: What is a Stock Split?
|
|
|
| Achaogen is a biopharmaceutical company engaged in discovering, developing, and commercializing antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. Co. develops plazomicin for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. Co. also develops antibacterial candidate, C-Scape, an orally-administered combination of ceftibuten and clavulanate for oral treatment for patients with cUTI, and acute pyelonephritis, caused by expanded spectrum beta-lactamases-producing Enterobacteriaceae. According to our AKAO stock split history records, AKAO has had 0 splits. | |
|
AKAO (AKAO) has 0 splits in our AKAO stock split history database.
Looking at the AKAO stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into AKAO shares, starting with a $10,000 purchase of AKAO, presented on a split-history-adjusted basis factoring in the complete AKAO stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
04/17/2014 |
|
| End date: |
04/26/2019 |
|
| Start price/share: |
$13.74 |
|
| End price/share: |
$0.11 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-99.20% |
|
| Average Annual Total Return: |
-61.72% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$80.06 |
|
| Years: |
5.03 |
|
|
|
|
|
